» Articles » PMID: 26770346

Effects of Diclofenac Sodium and Octreotide on Treatment of Caerulein-induced Acute Pancreatitis in Mice

Overview
Specialty General Medicine
Date 2016 Jan 16
PMID 26770346
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Research continues to develop novel therapeutic modalities that particularly focus on the pathogenesis of acute pancreatitis. This study aimed to assess the effects of diclofenac sodium and octreotide, alone or in combination, on pancreatic enzymes, pancreatic myeloperoxidase activity, histopathology and apoptosis of pancreas cells, using a model of experimentally induced acute pancreatitis.

Objectives: We aimed to demonstrate effects of diclofenac sodium, octreotide and their combined use on pancreatic enzymes, activity of pancreatic myeloperoxidase (MPO) activity, histopathology and apoptosis of pancreas on treatment of caerulin-induced experimental acute pancreatitis.

Materials And Methods: Caerulin-induced acute pancreatitis model was created using a total of 58 male BALB-C mice of 25 gr in seven groups. Serum amylase, lipase levels and pancreatic myeloperoxidase activity were examined as well as apoptotic values in pancreatic acinar cells through TUNNEL method. Histopathology of pancreas was evaluated for presence of edema, hemorrhage, parenchymal necrosis, fat necrosis, leukocyte infiltration, and fibrosis.

Results: In the diclofenac sodium group, apoptotic values in the pancreatic acinar cells were found to be statistically lower than in the acute pancreatitis group in terms of parenchymal necrosis and hemorrhage scores (P = 0.007, P = 0.002, and P = 0.052, respectively). No statistically significant differences were found in serum level of amylase, lipase, pancreatic myeloperoxidase activity and the other histopathological scores (P > 0.05).

Conclusion: Diclofenac sodium, a cost-effective agent with a favorable side-effect profile, may represent a novel therapeutic agent for the treatment of acute pancreatitis. Findings of this study suggest a better efficacy for diclofenac sodium monotherapy as compared to octreotide alone or octreotide/diclofenac combination.

Citing Articles

Involvement of heparanase in the pathogenesis of acute pancreatitis: Implication of novel therapeutic approaches.

Hamo-Giladi D, Fokra A, Sabo E, Kabala A, Minkov I, Hamoud S J Cell Mol Med. 2024; 28(17):e18512.

PMID: 39248454 PMC: 11382361. DOI: 10.1111/jcmm.18512.


A Systematic Review and Meta-analysis of Opioids vs Nonopioids in Acute Pancreatitis.

Nelson A, Lugo-Fagundo N, Mahapatra S, Cheungpastiporn W, Thongprayoon C, Wijarnpreecha K Gastro Hep Adv. 2024; 1(1):83-92.

PMID: 39129925 PMC: 11308224. DOI: 10.1016/j.gastha.2021.09.006.


Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression.

Lu Y, Gao J, Zhao C, Wen S, Tang C, Wang Y Sci Rep. 2018; 8(1):11033.

PMID: 30038293 PMC: 6056476. DOI: 10.1038/s41598-018-29349-y.

References
1.
Gong Z, Yuan Y, Lou K, Tu S, Zhai Z, Xu J . Mechanisms of Chinese herb emodin and somatostatin analogs on pancreatic regeneration in acute pancreatitis in rats. Pancreas. 2002; 25(2):154-60. DOI: 10.1097/00006676-200208000-00007. View

2.
Li J, Wang R, Tang C . Somatostatin and octreotide on the treatment of acute pancreatitis - basic and clinical studies for three decades. Curr Pharm Des. 2011; 17(16):1594-601. DOI: 10.2174/138161211796196936. View

3.
Foitzik T, Hotz H, Hotz B, Wittig F, Buhr H . Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepatogastroenterology. 2003; 50(52):1159-62. View

4.
Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V . Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998; 12(3):237-45. DOI: 10.1046/j.1365-2036.1998.00295.x. View

5.
You N, Tao K, Zhao W, Bao P, Li R, You H . Diphenhydramine modulates cytokines and induces apoptosis in experimental acute pancreatitis. Methods Find Exp Clin Pharmacol. 2010; 32(5):311-8. DOI: 10.1358/mf.2010.32.5.1428739. View